Recent studies have shown that Nocardia asteroides isolates have five major antibiotic resistance patterns; one of these patterns identifies isolates of Nocardiafarcinica. In the current study, we investigated a second pattern characterized by susceptibility to ampicillin and erythromycin. This pattern was seen in 17% of 223 clinical isolates identified by standard techniques as N. asteroides and associated with diseases typical for nocardiae. Biochemically, isolates with this drug pattern were relatively homogeneous and identical to the type strain and previous descriptions of Nocardia nova. The strains studied were unique among nocardiae in having both aand f-esterase activity (85 and 95%, respectively). However, the arylsulfatase activity at 14 days (75%) and antimicrobial susceptibility patterns, including susceptibility to erythromycin (100%), were the only routinely available methods that would separate N. nova strains from other members of N. asteroides. N. asteroides should be considered a complex because current clinical identification schemes include isolates of N. farcinica and N. nova and may well include additional species. This is the first detailed description of N. nova as a pathogen in humans.
Numerous taxonomic studies have established the heterogeneity of the species Nocardia asteroides by using a variety of parameters including numerical taxonomy (5, 6, 11, 13) , antigen-induced delayed hypersensitivity (8) , DNA homology (4), and antimicrobial susceptibility (16) . Current methods of recognition of N. asteroides in the clinical laboratory include microscopic and colonial morphology, inability to hydrolyze casein, tyrosine, xanthine, or hypoxanthine, and resistance to lysozyme. Unfortunately, additional species, including Nocardiafarcinica, N. carnea, and N. nova, share the same features (7) and have undoubtedly contributed to the apparently heterogeneous nature of N. asteroides. Because of the taxonomic diversity of N. asteroides and the knowledge that it currently contains several species, we have chosen to call it the N. asteroides complex.
In 1988, a susceptibility study of 78 clinical isolates of the N. asteroides complex from the United States found 95% of strains to exhibit one of five antibiotic resistance patterns (16) . Studies were then undertaken to determine whether these drug patterns correlated with specific taxonomic groups or recognized species. The first pattern studied (called type 5) was seen in approximately 20% of the isolates, including essentially all isolates in the N. asteroides complex that are resistant to cefotaxime, ceftriaxone, and cefamandole. Recent studies have established these isolates as N. farcinica (17) .
We studied a second drug group (type 3) that comprises approximately 20% of the strains and is characterized by susceptibility to ampicillin and erythromycin (16) . The current study demonstrates that these isolates are members of the new species N. nova (13, 18) and provides the first detailed description of clinical disease and drug susceptibilities in this species. * (16) . Clinical information on the isolates was obtained by correspondence and/or by telephone with the referring laboratory or physician. Information was also sought on eight type 3 isolates from the Texas Laboratory identified before 1983.
All isolates had previously been identified as belonging to the N. asteroides complex by standard methods (9) , the majority by the Mycology Section of the Texas Department of Health, Austin. After initial testing, the isolates had been stored at -70°C in tryptic soy broth with 15% glycerol.
The type strain of N. nova (ATCC 33726) and the co-type strain (ATCC 33727) were provided for study by M. Tsukamura (National Chubu Hospital, Obu, Aichi, Japan), who had originally submitted these strains to the American Type Culture Collection. Twelve additional strains identified only as N. asteroides were provided by the American Type Culture Collection and were screened for the type 3 drug pattern.
Susceptibility testing. Testing for susceptibility to ampicillin, carbenicillin, cefamandole, cefotaxime, ceftriaxone, imipenem, erythromycin, minocycline, doxycycline, ciprofloxacin, sulfamethoxazole, amoxicillin-clavulanic acid (2:1), and amikacin was performed by broth microdilution in cation-supplemented Mueller-Hinton broth as previously described (13) Laboratory identification. All isolates were initially identified as belonging to the N. asteroides complex by using standard tests that included colony and microscopic morphology, susceptibility to lysozyme, and failure to hydrolyze casein, xanthine, tyrosine, or hypoxanthine (8) .
Twenty clinical isolates with the type 3 drug pattern were randomly chosen and, along with the type strain and co-type strain of N. nova, were submitted to the National Chubu Hospital, where they were tested against 107 characteristics as previously described (13) . These include growth characteristics, requirement of numerous carbohydrates as nitrogen and carbon sources, enzyme production, and growth inhibition by numerous drugs and chemical compounds.
These 20 isolates were also tested again for susceptibility to lysozyme, hydrolysis patterns, and acid production from 23 carbohydrates at the Mycology Laboratory of the Centers for Disease Control.
Because only one of the tests identified in the study of these 20 strains as being useful in separating N. nova from other groups in the N. asteroides complex is commercially available (i.e., the arylsulfatase reaction), we studied susceptibility to erythromycin by disk diffusion as a possible additional test for the recognition of N. nova. With a disk diffusion method (15) with a disk zone size of 30 mm or greater on a commercial disk containing 15 ,ug of the antimicrobial agent as the breakpoint, all available clinical isolates of N. nova were compared with 40 isolates of N. farcinica (17) and 40 isolates of the N. asteroides complex that excluded isolates of N. nova and N. farcinica and included only members of the three remaining antibiotic resistance groups (types 1, 4, and 6). The arylsulfatase reaction at 2 weeks was also tested on all N. nova isolates by using a commercial system (Remel, Lenexa, Kans.). The degree of positivity was recorded (0 to 4+, with 0 or + reactions considered negative). Four tests recommended for identification of N. farcinica (equivalent confluent growth on tryptic soy agar at 35°C and 45°C after 3 days, acid production from rhamnose, utilization of acetamide as a nitrogen and carbon source, and resistance to cefamandole and tobramycin) (17) Table 2 . Unusual features were the presence of a-and ,B-esterase activities (85 and 95%, respectively) and arylsulfatase activity at 2 weeks (80% of strains). The strains were able to utilize fructose, glucose, and glycerol as sole carbon sources but were negative for essentially all other carbohydrates, including citrate. The acid production pattern was generally similar to that for utilization as a sole carbon source. The results of these tests are almost identical to those of the three culture collection strains of N. nova (Table 2 ) and previous descriptions of strains of N. nova, including the type strain (13, 18 of N. nova (the same strains used in the susceptibility tests). Selected tests, including erythromycin susceptibility, were then performed with all 40 strains of N. nova, and the results were compared with those from 40 strains of N. farcinica and 40 other strains of the N. asteroides complex. (Some of these tests in the latter two groups were published in a prior study of N. farcinica [17] .) The arylsulfatase activity at 14 days was identified in 75% of the N. nova strains compared with only 1 of the 65 control strains. Among the 30 isolates of N. nova with positive reactions, 6 (20%) were 1+, 12 (40%) were 2+, 10 (25%) were 3+, and 1 (5%) was 4+. Twelve isolates with positive reactions (1+ through 4+) were retested in the same laboratory or different laboratories. Eleven were again positive for arylsulfatase in the 1 + to 4+ range, whereas one gave a + reaction. With repeat testing of 10 isolates with negative or ± reactions, 3 were 3+, 3 were 1+, and the remainder were unchanged. The major problem with isolates that gave false-negative results appeared to be insufficient growth (cell mass) in the substrate medium. All isolates (100%) of N. nova were susceptible to erythromycin ( Table 3 ). The four tests used to identify N. farcinica (17) separated these isolates from the other two groups. (The results for the four tests to identify N. farcinica with the 40 strains of N. farcinica and many of the isolates of the N. asteroides complex were published previously [17] .) DISCUSSION The clinical and taxonomic status of N. nova has been uncertain since the species was first described in 1982 (13) . At that time, Tsukamura described 14 strains that could be separated by numerical analysis from N. farcinica and other isolates of N. asteroides. The unusual features of these strains were the presence of arylsulfatase activity at 14 days (71% of strains) and esterase activity (64% of strains). Two isolates were from patients believed to have pulmonary infections. Taxonomists were uncertain of the status of these strains, and in the (latest) 1986 edition ofBergey's Manual of Systematic Bacteriology, N. nova was listed as a species incertae sedis (7).
Recently, however, Yano et al. (18) performed DNA homology studies and showed that the type strain of N. nova (ATCC 33726) had only 20% homology with the type strain of N. farcinica (ATCC 3318) and 39% homology with the type strain of N. asteroides (ATCC 19247) , establishing the species status of N. nova. These authors also observed differences in mycolic acid content between the three species and noted that isolates of N. nova had a-esterase activity as well as ,B-esterase activity (18) . No studies of the clinical importance of N. nova have been reported, however. The current study shows that approximately 20% of clinical isolates from two areas of the United States (Texas and Minnesota) identified as N. asteroides are actually isolates of N. nova. The clinical diseases with these isolates (pneumonia, cutaneous infections, brain abscess, etc.) and the clinical settings (trauma, corticosteroid use, organ transplantation, etc.) were similar to those in previous descriptions of diseases due to N. farcinica (15) and to the N. asteroides complex in reports in which the species were not distinguished (1, 2) .
Methods for clinical identification of N. nova are problematic. Carbohydrate utilization tests and currently available biochemical reactions do not separate N. nova from remaining isolates in the N. asteroides complex. At present, 2-week arylsulfatase activity and susceptibility to erythromycin offer the best clinical means of identification, since no other group within the N. asteroides complex has this drug pattern (16) . Additional diagnostic tests that are readily available to the clinical laboratory and that are both sensitive and specific for N. nova are needed.
The first description of antibiotic resistance patterns in 78 isolates of the N. asteroides complex found 95% of strains to have one of five patterns (16 drug resistance pattern that does not match that of any of the common groups. Thus the status of the other three groups is uncertain. Are they also separate species that have been missed because of the complexity of the isolates identified as N. asteroides, or are they only subgroups with different biochemical and drug features? Clearly, DNA homology studies will be needed to determine their taxonomic status. Until that time and until laboratories are able to separate N. nova and N. farcinica from the "real" N. asteroides, we strongly recommend that isolates identified by current standard laboratory criteria be identified only as N. asteroides complex.
The distinguishing drug pattern of N. nova strains is their susceptibility to ampicillin and erythromycin. A study by Finland et al. showed that in combination these two drugs act synergistically against the majority of isolates of the N. asteroides complex (3) . In addition, they described a single patient whose disease had not responded to therapy with a sulfonamide but who responded clinically and microbiologically to the combination of ampicillin and erythromycin. One of the patients in the current study had a sulfonamide allergy, and we treated him with erythromycin alone after a course of parenteral amikacin and ceftriaxone; this resulted in a cure of his disease (14) . These findings combined with the current MIC results suggest that erythromycin alone or in combination with ampicillin (but not amoxicillin-clavulanic acid) offers a potential oral therapy for patients with N. nova who cannot tolerate or do not respond to sulfonamide therapy.
Another unusual susceptibility feature of these isolates of N. nova is their moderate susceptibility to ampicillin but resistance to carbenicillin and the combination of amoxicillin and clavulanic acid. The apparent reason for this unusual P-lactam antibiotic resistance pattern is that isolates of N.
nova have an inducible membrane-bound P-lactamase with penicillinase activity. This enzyme is not induced by ampicillin but is induced by carbenicillin and clavulanic acid. The isolates of N. nova had a single ,-lactamase pattern for isoelectric focusing, again supporting the homogeneous nature of these isolates (12) . Studies of the P-lactamase activity in N. nova are ongoing.
